Key facts
- Tactical Therapeutics’s last known valuation is $100.0M.
- It has raised $65.0M; the latest was Later Stage VC ($35.0M) in Jan 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Tactical Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tactical Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tactical Therapeutics
Developer of a clinical-stage brain penetrant drug designed to inhibit calcium signaling pathways involved in cancer progression and drug resistance. The company offers oral, first-in-class therapy, enabling patients with glioblastoma and solid tumors to have improved survival and enhanced treatment effectiveness.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2005
- Employees
- 2
- Website
- tacticaltherapeutics.com/
- Ownership
- Privately Held (backing)
Tactical Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tactical Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tactical Therapeutics in its N-PORT filings yet. We sweep new filings monthly.